- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01722916
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
February 1, 2024 updated by: Murad Alam, Northwestern University
Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical Trial
The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
5
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Department of Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 18 and over
- The subjects are in good health
- The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator
Exclusion Criteria:
- Under 18 years of age
- Pregnancy or Lactation
- Subjects who are unable to understand the protocol or to give informed consent
- Subjects with mental illness
- Recent Accutane use in the past 6 months
- Subjects prone to hypertrophic and keloidal scarring
- Subjects with tattoos and/or scars on upper medial arms (the treatment area)
- Subjects with known hypersensitivity to hyaluronic acid
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose of Hyaluronidase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose of hyaluronidase injected until the filler is no longer detectable
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Murad Alam, MD, Northwestern University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 5, 2012
First Submitted That Met QC Criteria
November 5, 2012
First Posted (Estimated)
November 7, 2012
Study Record Updates
Last Update Posted (Estimated)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- STU68166
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Safety
-
University of DundeeNHS Tayside; NHS FifeCompleted
-
Entera Bio Ltd.Completed
-
West China HospitalCompleted
-
Nanjing Ruijie Pharma Co., Ltd.Recruiting
-
Prolong PharmaceuticalsTerminated
-
SignPath Pharma, Inc.Completed
-
Madrigal Pharmaceuticals, Inc.Completed
-
Mahidol UniversitySiriraj HospitalUnknown
-
Madrigal Pharmaceuticals, Inc.Completed
-
University of Missouri-ColumbiaNational Center for Complementary and Integrative Health (NCCIH); University...Completed
Clinical Trials on Hyaluronidase
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompletedDiabetic Retinopathy | Vitreous HemorrhageUnited States, Canada, Mexico
-
Halozyme TherapeuticsBaxter Healthcare CorporationCompleted
-
Vanderbilt University Medical CenterBaxter Healthcare CorporationCompletedDehydration | Pediatrics | Cardiac OutputUnited States
-
University of NebraskaRecruiting
-
Brigham and Women's HospitalWithdrawnMorphea | Scleroderma | CREST Syndrome | Microstomia | Scleromyxedema
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompletedDiabetic Retinopathy | Vitreous DetachmentUnited States
-
BMI KoreaCompletedHealth, SubjectiveKorea, Republic of
-
Halozyme TherapeuticsBaxter Healthcare CorporationCompleted